Drug intelligence / Profile preview

Berubicin (CNS Pharmaceuticals)

Development stage: Unknown
Lead developer: CNS Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Berubicin is a chemical compound developed as an anticancer agent. It was initially developed by Reata Pharmaceuticals through Phase 1 clinical trials. CNS Pharmaceuticals subsequently acquired all rights and obtained a worldwide exclusive license for Berubicin (also known as WP744) from Houston Pharmaceuticals, Inc. It is being investigated for the treatment of recurrent Glioblastoma Multiforme (WHO Grade IV) and CNS lymphomas. A specific formulation, Berubicin Hydrochloride, is administered intravenously.

Other names: Berubicin Hydrochloride

Targets

DNATOP2A (DNA topoisomerase II)

Beyond the preview

Go deeper on Berubicin (CNS Pharmaceuticals).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berubicin (CNS Pharmaceuticals).

Explore the full profile